Results

Halted in US by FDA hold, Bellicum buoyed by some positive numbers from its European T cell study for pediatric AML

Shares of Bellicum Pharmaceuticals $BLCM got a badly needed boost this morning as the biotech — put in at least temporary limbo by an FDA hold on its lead T cell therapy — plucked some encouraging data from a European study for children with acute myeloid leukemia.

Neena Kapoor

Among 38 pediatric AML patients treated with BPX-501 following haploidentical hematopoietic stem cell transplant, researchers tracked a median relapse-free rate of 91.5% and overall survival of 97.3% during a one-year followup in their BP-004 study in Europe. There’s no control group to compare against, but the beleaguered biotech pointed to historical rates of 60% to 80% following alternate-donor HSCT.

The biotech’s execs say this gives them confidence in setting up a registration study. And its stock jumped 12% in pre-market trading.

Right now, Bellicum is doing everything it can to try and make it appear that life and work goes on as normal. But that’s a tough trick for a company which was sent into a tailspin a few weeks ago after regulators halted their US studies of BPX-501 following several cases of brain damage. The Houston-based outfit sought to reassure investors that it would finish the pediatric AML study and later suggested that it could get out from under the FDA hold in a relatively short period.

The FDA, though, is reliably close-lipped about experimental meds and there are no guarantees.

The biotech has been studying this cell therapy for three key objectives: fighting infection, supporting engraftment, and preventing disease relapse and, should GvHD occur, their CaspaCIDe safety switch can be activated to kill the toxic T cells.

“The recurrence of cancer is one of the most serious risks to AML patients receiving a stem cell transplant. These impressive results in children with AML suggest that BPX-501 may be effectively reducing or eradicating residual cancer cells following a haplo-transplant procedure,” commented Neena Kapoor, director of the Blood and Marrow Transplantation Program at Children’s Hospital of Los Angeles and an investigator in the BP-004 trial.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->